GlassScriptPhysician profile
Richard K Cavender
NPI 1073628533
$2,211.02
in general payments reported to CMS, 2019-2025
17 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $316 · 2021: $311 · 2022: $565 · 2023: $284 · 2024: $19.71 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $633.55 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $350.42 | 2019-2023 | Repatha |
| Lilly USA, LLC | $165.81 | 2022-2024 | Zepbound |
| Currax Pharmaceuticals LLC | $147.83 | 2019-2023 | Contrave, Nexlizet, Nexletol |
| Kowa Pharmaceuticals America, INC. | $144.88 | 2019-2022 | |
| Antares Pharma, INC. | $139.06 | 2019-2021 | |
| Abbvie INC. | $120.92 | 2019-2023 | Synthroid |
| Corcept Therapeutics | $120.50 | 2023-2025 | Korlym |
| Amarin Pharma, INC. | $102.15 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $79.12 | 2022-2023 | Farxiga |
| Vivus LLC | $55.43 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $43.65 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $43.36 | 2019 | |
| Avion Pharmaceuticals | $16.68 | 2022 | |
| Ibsa Pharma INC. | $16.56 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $15.94 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Cavender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.